Integrin Alpha V Beta 3-targeting Protein ACT50 clinical trials
Also written ACT50.
How each study uses Integrin Alpha V Beta 3-targeting Protein ACT50 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Integrin Alpha V Beta 3-targeting Protein ACT50 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ACT50
- 3
Studies by the year they started
3 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
ProDa BioTech, LLC (2) · University of Alabama at Birmingham (1)
Often tested with
Tested in the same studies.
FOLFIRI-Ziv-aflibercept Regimen (1) · FOLFIRI Regimen (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Integrin Alpha V Beta 3-targeting Protein ACT50.
- Jul 2027ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast CancerPhase 1/2 · ProDa BioTech, LLC
Studies
Open first, then newest update. How each study uses Integrin Alpha V Beta 3-targeting Protein ACT50 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast CancerRecruitingPhase 1/2ProDa BioTech, LLCNCT06460298Written as ProAgio Dose Levels (DL) 1,2,3,4How we know
- Trial of ProAgio in Advanced/Metastatic Colorectal CancerSuspendedPhase 1University of Alabama at BirminghamNCT06867822Written as ProAgioHow we know
- ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor MalignanciesCompletedPhase 1ProDa BioTech, LLCNCT05085548Written as ProAgio Dose Levels (DL) 1,2,3How we know